A new direction for the treatment of cholangiocarcinoma (CCA) was addressed by Yang et al. where miR-144 could induce resistance to chemotherapy via the miR-144/LIS1/AKT pathway 103. Here, PAFAH1B1 is linked to cholangiocarcinoma.